Jane Street’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-580,600
Closed -$74.4M 10811
2025
Q2
$74.4M Sell
580,600
-146,600
-20% -$15.2M 0.01% 576
2025
Q1
$64.4M Sell
727,200
-49,600
-6% -$4.84M 0.02% 533
2024
Q4
$67.8M Sell
776,800
-604,700
-44% -$55.4M 0.01% 567
2024
Q3
$128M Sell
1,381,500
-78,800
-5% -$7.83M 0.03% 321
2024
Q2
$157M Buy
1,460,300
+847,400
+138% +$84.8M 0.04% 260
2024
Q1
$58.1M Buy
612,900
+81,800
+15% +$7.02M 0.01% 562
2023
Q4
$49M Buy
531,100
+463,500
+686% +$30M 0.01% 689
2023
Q3
$3.39M Buy
67,600
+7,400
+12% +$395K ﹤0.01% 3181
2023
Q2
$3.8M Sell
60,200
-86,700
-59% -$4.71M ﹤0.01% 3133
2023
Q1
$6.61M Buy
146,900
+48,200
+49% +$2.17M ﹤0.01% 2089
2022
Q4
$4.32M Sell
98,700
-7,600
-7% -$364K ﹤0.01% 2677
2022
Q3
$7M Buy
106,300
+61,200
+136% +$3.93M ﹤0.01% 2126
2022
Q2
$2.28M Buy
45,100
+22,700
+101% +$1.33M ﹤0.01% 3914
2022
Q1
$1.43M Buy
22,400
+18,100
+421% +$1.3M ﹤0.01% 5389
2021
Q4
$461K Buy
4,300
+1,500
+54% +$157K ﹤0.01% 7425
2021
Q3
$288K Sell
2,800
-24,900
-90% -$2.32M ﹤0.01% 8266
2021
Q2
$2.44M Buy
27,700
+3,900
+16% +$357K ﹤0.01% 3946
2021
Q1
$2.31M Sell
23,800
-1,200
-5% -$120K ﹤0.01% 3742
2020
Q4
$2.8M Buy
25,000
+7,200
+40% +$759K ﹤0.01% 2909
2020
Q3
$1.65M Sell
17,800
-28,900
-62% -$2.23M ﹤0.01% 3327
2020
Q2
$3.64M Buy
46,700
+22,900
+96% +$1.55M ﹤0.01% 2240
2020
Q1
$1.39M Buy
+23,800
New +$1.53M ﹤0.01% 2410

Other funds holding BPMC

Jane Street's BPMC Position: Q3 2025 in Review

Jane Street sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 214,394 shares — an estimated $27.5M sold.

Jane Street first reported a position in BPMC in Q1 2017 and held it in 28 quarters. The position peaked at $35.6M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Jane Street reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Jane Street sold 214,394 Blueprint Medicines shares in Q3 2025, an estimated $27.5M.
  • Jane Street first reported a position in Blueprint Medicines in Q1 2017 and held it in 28 quarters.
  • Jane Street's Blueprint Medicines position peaked at $35.6M in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.